Vitamin D supplementation in obese type 2 diabetes subjects in Ajman, UAE: a randomized controlled double-blinded clinical trial

• Published in: European journal of clinical nutrition Vol. 69; no. 6; pp. 707 - 711
• Main Authors: Sadiya, A, Ahmed, S M, Carlsson, M, Tesfa, Y, George, M, Ali, S H, Siddieg, H H, Abusnana, S
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.06.2015; Nature Publishing Group
• Subjects: 692/699; Adult; Alfacalcidol; Blood pressure; Body Mass Index; Calcifediol; Calcifediol - blood; Care and treatment; Cholecalciferol - administration & dosage; Cholecalciferol - adverse effects; Cholecalciferol - therapeutic use; Clinical Nutrition; Diabetes; Diabetes Mellitus, Type 2 - complications; Diabetes therapy; Dietary supplements; Dietary Supplements - adverse effects; Double-Blind Method; Epidemiology; Female; Glycated Hemoglobin A - analysis; Health aspects; Humans; Hyperparathyroidism, Secondary - epidemiology; Hyperparathyroidism, Secondary - etiology; Hyperparathyroidism, Secondary - prevention & control; Incidence; Internal Medicine; Lipids; Lost to Follow-Up; Male; Medicine; Medicine & Public Health; Metabolic Diseases; Metabolism; Methods; Middle Aged; Obesity; Obesity - complications; Original; original-article; Overweight persons; Parathyroid Hormone - blood; Patient Dropouts; Public Health; Thyroid; Type 2 diabetes; United Arab Emirates - epidemiology; Vitamin D; Vitamin D Deficiency - blood; Vitamin D Deficiency - complications; Vitamin D Deficiency - drug therapy; Vitamin D Deficiency - physiopathology; United Arab Emirates
• ISSN: 0954-3007; 1476-5640; 1476-5640
• DOI: 10.1038/ejcn.2014.251

Objectives: To study the effect of Vitamin D 3 supplementation on metabolic control in an obese type 2 diabetes Emirati population. Methods: This randomized double-blind clinical trial was conducted with 87 vitamin D-deficient obese, type 2 diabetic participants. The vitamin D-group ( n =45) and the placebo group ( n =42) were matched for gender, age, HbA1c and 25-hydroxy vitamin D (25(OH) D) at the baseline. The study was divided into two phases of 3 months each; in phase 1, the vitamin D-group received 6000 IU vitamin D 3 /day followed by 3000 IU vitamin D 3 /day in phase 2, whereas the placebo group ( n =42) received matching placebo. Results: After supplementation, serum 25(OH) D peaked in the vitamin D-group in phase 1 (77.2±30.1 nmol/l, P =0.003) followed by a decrease in the phase 2 (61.4±18.8 nmol/l, P =0.006), although this was higher compared with baseline. In the placebo group, no difference was observed in the serum 25(OH) D levels throughout the intervention. Relative to baseline serum, parathyroid hormone decreased 24% ( P =0.003) in the vitamin D-group in phase 2, but remained unchanged in the placebo group. No significant changes were observed in blood pressure, fasting blood glucose, HbA1c, C-peptide, creatinine, phosphorous, alkaline phosphatase, lipids, C-reactive protein or thyroid stimulating hormone concentrations compared with baseline in either group. Conclusions: Six months of vitamin D 3 supplementation to vitamin D-deficient obese type 2 diabetes patients in the UAE normalized the vitamin D status and reduced the incidence of eucalcemic parathyroid hormone elevation but showed no effect on the metabolic control.